- Also known as
- Bremelanotide · BMT · Vyleesi (US brand)
- Class
- Melanocortin receptor agonist at MC3R and MC4R; a cyclic alpha-MSH analogue
- Form
- Lyophilised powder in 10 mg vials, plus a ready-mixed nasal spray
- Sizes
- 10 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 10 mg: 2 mL
- Molecular weight
- 1025.2 g/mol
What is PT-141?
In chemical terms PT-141 is classed as a melanocortin receptor agonist (MC3R and MC4R; cyclic alpha-MSH analogue). The molecular weight is 1025.2 g/mol. Across the literature the same substance turns up under several names, among them Bremelanotide, BMT and Vyleesi (US brand). The recorded sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH; the C-terminal free acid of the Melanotan II ring. The published research is in human work. 8 of the 8 studies listed below are controlled trials in people. We supply it as a lyophilised powder in 10 mg vials and as a ready-mixed nasal spray from Canadian stock, for laboratory research. None of this is a medicine, and it is not for human or veterinary use.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Kingsberg SA et al.2019 · Obstet Gynecol · PMID 31599840 | Human, two randomised controlled phase 3 trials (RECONNECT; n=1,267 randomised; premenopausal women with HSDD) | 1.75 mg subcutaneous, as needed | 24 weeks | Compared with placebo, bremelanotide increased sexual desire (integrated 0.35, P<.001) and reduced distress related to low desire (integrated −0.33, P<.001). Nausea, flushing and headache were more common with bremelanotide. |
| Clayton AH et al.2022 · J Womens Health (Larchmt) · PMID 35147466 | Human, integrated safety review of phase 1–3 programme (3,500 subjects, 43 studies; phase 3 double-blind n=1,247) | Not stated in the abstract (dosed per label in phase 3) | Up to 18 months in phase 3 | The most common adverse events versus placebo were nausea (40.0% vs 1.3%), flushing (20.3% vs 1.3%), headache (11.3% vs 1.9%) and injection site reactions (5.4% vs 0.5%). Small, transient blood pressure rises were seen. |
| Clayton AH et al.2016 · Womens Health (Lond) · PMID 27181790 | Human, randomised placebo-controlled dose-finding trial (efficacy n=327; premenopausal women) | 0.75, 1.25 or 1.75 mg subcutaneous, as desired | 12 weeks | For the pooled 1.25/1.75 mg groups, satisfying sexual events rose by 0.7 a month versus 0.2 on placebo (p=0.0180), with better sexual function and distress scores. Adverse events were nausea, flushing and headache. |
| White WB et al.2017 · J Hypertens · PMID 27977473 | Human, randomised double-blind placebo-controlled trial (n=397 premenopausal women) | 0.75, 1.25 or 1.75 mg subcutaneous | Two doses 24 h apart, ambulatory monitoring | Systolic pressure rose by up to about 3 mmHg versus placebo in the 4 h after dosing, with peaks usually under 15 minutes. At 1.75 mg, heart rate fell by 4.6–4.7 bpm. |
| Safarinejad MR et al.2008 · J Urol · PMID 18206919 | Human, randomised double-blind placebo-controlled trial (n=342 men with erectile dysfunction not responding to sildenafil) | 10 mg intranasal, 45 minutes to 2 hours before sexual stimulation | At least 16 attempts at home | Positive clinical results were reported in 33.5% on bremelanotide versus 8.5% on placebo (p=0.03), with greater intercourse satisfaction. Drug-related adverse effects were more frequent with bremelanotide. |
| Rosen RC et al.2004 · Int J Impot Res · PMID 14999221 | Human, phase 1/2 randomised trials (healthy men; men with inadequate response to Viagra) | 0.3–10 mg subcutaneous in healthy men; 4 or 6 mg in ED patients (crossover) | Single doses | Doses above 1.0 mg produced a significant erectile response on RigiScan in healthy men, and both 4 and 6 mg worked in ED patients. PT-141 was well tolerated in both studies. |
| Diamond LE et al.2005 · Urology · PMID 15833522 | Human, randomised crossover trial (n=19 men with erectile dysfunction) | 7.5 mg intranasal PT-141 with 25 mg sildenafil | Single doses; 6-hour post-dose assessment | PT-141 plus sildenafil produced a significantly greater erectile response than sildenafil alone. The combination did not bring new or more frequent adverse events. |
| Diamond LE et al.2006 · J Sex Med · PMID 16839319 | Human, randomised double-blind crossover trial (n=18 premenopausal women with sexual arousal disorder) | 20 mg intranasal, single dose | Single session, 24-hour follow-up | More women reported moderate or high desire after bremelanotide than after placebo (P=0.0114). Vaginal vasocongestion did not change significantly. |
What these studies don't show: Controlled human data does exist, but its scope is limited. The enrolment, the measures chosen and the length of follow-up each bound what the results can mean. Nothing here speaks to use beyond the trial protocol. Testing confirms identity and purity; it is not evidence of an effect.
Every study links to its PubMed record. See all PT-141 studies in the research library →
PT-141 price in Canada: 10mg vial
Buy PT-141 in Canada in a 10mg vial, plus a nasal spray and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 10 mg | $43.00 | $4.30/mg |
Other formats and kits
Is PT-141 available in Canada?
PT-141 carries no Drug Identification Number, which is how Health Canada marks a drug it has authorized. Its safety, efficacy and quality have never been assessed by a regulator in Canada. Borealis Peptides supplies it for in-vitro laboratory research only, not for human or veterinary use. How Health Canada treats research peptides →
Side effects reported in studies
Where a cited study said anything about tolerability, its exact wording is reproduced below. Human work on this scale cannot build a safety profile. Read more →
Doses used in studies
PT-141 FAQ
What is PT-141?
In chemical terms PT-141 is classed as a melanocortin receptor agonist (MC3R and MC4R; cyclic alpha-MSH analogue). The published research is in human work. Borealis Peptides offers it as a lyophilised powder in 10 mg vials and as a ready-mixed nasal spray for in-vitro laboratory research. It is no medicine and is not for use in humans or animals. Each cited paper below appears with the system it used and what it turned up.
Where can I buy PT-141 in Canada?
We ship it inside Canada from our own stock, in 10 mg vials. Nothing goes out until HPLC has confirmed identity and purity for that batch. Borealis Peptides takes research orders only and delivers to research and business addresses. Identity and purity are checked per batch, and the paperwork names that batch specifically.
Is PT-141 legal in Canada?
PT-141 carries no Drug Identification Number, which is how Health Canada marks a drug it has authorized. Its safety, efficacy and quality have never been assessed by a regulator in Canada. Borealis Peptides supplies it for in-vitro laboratory research only, not for human or veterinary use. Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, so we take it to set the terms of supply, never to clear the material for use.
How much PT-141 should I use?
Borealis Peptides provides no dosing, protocols or reconstitution volumes, and will not supply them if asked. In the lab the quantity is dictated by the study design, something a supplier cannot reasonably set. The figures shown here are what particular published studies used within their own models: a record of past work, not a recommendation.
What human evidence is there for PT-141?
Of the 8 studies cited, 8 are controlled trials in people and the rest are animal or cell work. Each row names its model, the amount used and what the authors reported, so the weight of each study can be judged directly rather than through a summary.
How is PT-141 stored?
Keep sealed vials at −20 °C, dry and dark. After reconstitution, 2–8 °C. The lyophilised powder withstands ambient temperature in transit, so it ships without ice and goes into the fridge on arrival. Light and repeated warming harm it more than the trip itself.
Does PT-141 need bacteriostatic water?
The nasal spray comes as a finished solution in its own bottle, so nothing is added to it: no bacteriostatic water, no mixing, no transfer. Only the lyophilised vial is supplied dry, and that is the single format bacteriostatic water is relevant to. It is sold separately.
How is the purity of PT-141 confirmed?
HPLC confirms identity and purity for every batch, not just once per product. The certificate names the batch it covers, and that batch number sits on the vial, so any result can be traced back to the exact material behind it. Ask with your order number and we will send it.
How does PT-141 compare with Melanotan II and Melanotan I?
They are not interchangeable, and this page makes no claim that one is preferable. Melanotan II and Melanotan I have 8 cited studies and 8 cited studies on their page against 8 here. What sets them apart is the published work, which both pages lay out in full.
Why is PT-141 named in a Health Canada advisory?
Because it was one of the peptides seized from sellers putting unauthorized injectable products online. The advisory addresses material sold for people to inject without authorization. Borealis Peptides offers research material for in-vitro laboratory work and nothing for injection or for any use in a person, which is the distinction the advisory is drawn around.








